Kevin Eisenfrats, Contraline CEO
September 10, 2024 11:31 AM EDTUpdated 12:06 PM
Startups
R&D

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Ryan Cross

Senior Science Correspondent

A re­versible male con­tra­cep­tive could be a lot clos­er to re­al­i­ty than you think.
Ear­li­er this sum­mer, doc­tors were tan­ta­lized by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times